Amanote Research
Register
Sign In
P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1665
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
W. Wang
C. Xu
W. Zhuang
Z. Song
Y. Huang
Y. Chen
G. Chen
M. Fang
T. Lv
Y. Song
Publisher
Elsevier BV
Related search
ROS1-ADGRG6: A Case Report of a Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
BMC Cancer
Cancer Research
Oncology
Genetics
A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Chemotherapy Combined With Bevacizumab for the Treatment of Advanced Lung Adenocarcinoma Cancer Harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 Mutations: A Case Report
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.cr-11 ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Successful Erlotinib Rechallenge for Leptomeningeal Metastases of Lung Adenocarcinoma After Erlotinib-Induced Interstitial Lung Disease: A Case Report and Review of the Literature
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Successful Rechallenge With Reduced Dose of Erlotinib in a Patient With Lung Adenocarcinoma Who Developed Erlotinib‑associated Leukocytoclastic Vasculitis: A Case Report
Oncology Letters
Cancer Research
Oncology